About Avelas
Avelas Biosciences is a clinical-stage oncology company focused on developing AVB-620, a novel drug-device combination product for use during cancer surgery. AVB-620 helps improve surgery by detecting cancer in real-time and has the potential to become part of standard-of-care treatment for a variety of cancer surgeries.
Avelas is currently in a Phase II/III registration trial for the use of AVB-620 during breast cancer surgery.
Latest News
-
May 19, 2020
Avelas and AxelaRx Announce Collaboration to Accelerate the Development of Promising Nerve Imaging Agents
Read more -
Feb 26, 2020
Avelas Biosciences Voted Innovator of the Year at Field Service Medical 2020
Read more -
Nov 22, 2019
Avelas Welcomes Susan Stimson to its Board of Directors
Read more